UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of report (Date of earliest event reported): ~~August~~May 31, ~~2023~~2024

HEALTH DISCOVERY CORPORATION

(Exact name of registrant as specified in charter)

333-62216

74-3002154

(State of incorporation)

(Commission File Number)

(IRS Employer

Identification No.)

2002 SUMMIT BLVD, SUITE 300
ATLANTA, GA		30319
(Address of principal executive offices)		(Zip Code)

(404) 566-4865

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act.

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act.

☐ Pre-commencement communications pursuant to Rule 14d–2(b) under the Exchange Act.

☐ Pre-commencement communications pursuant to Rule 13e–4(c) under the Exchange Act.

Securities registered pursuant to Section 12(g) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, no par value	HDVY	N/A

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 54.0201 ~~Departure~~Changes ofin ~~Directors~~Registrant’s orCertifying ~~Certain Officers; Election of Directors; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers~~Accountant.

~~William~~On F.May ~~Fromholzer~~31, at 2024, the ~~age~~ Board of ~~77,~~Directors ~~will~~received ~~retire~~notice from ~~the~~Frazier ~~board~~& ofDeeter, ~~directors~~LLC ~~of Health Discovery Corporation~~ (~~the~~ “~~Company”)~~Frazier by& ~~October 1~~Deeter”), ~~2023. Mr. Fromholzer issued~~ the ~~following~~independent ~~statement:~~registered ~~“My~~public ~~tenure~~accounting firm ~~as a director was one~~ of ~~the~~Health ~~great~~Discovery ~~experiences~~Corporation ~~of my career and I look forward to watching~~ (the “Company”), ~~continue~~that tothey ~~move~~were ~~forward~~resigning ~~with~~as ~~SVM-RFE in~~ the ~~world~~Company’s ofregistered ~~AI and in the development of identifying early stage~~accounting ~~diagnostics~~firm ~~for~~effective ~~common health issues~~immediately.”

~~Item~~The ~~7.01~~reports ~~Regulation~~of FDFrazier ~~Disclosure~~& Deeter on the financial statements of the Company for the fiscal year ended December 31, 2020, did not contain any adverse opinion or disclaimer of opinion and were not qualified or modified as to uncertainty, audit scope or accounting principles, except the opinion included an explanatory paragraph referring to the Company’s ability to continue as a going concern.

OnDuring ~~August~~the ~~31, 2023, Health~~Company’s ~~Discovery~~two ~~Corporation~~most ~~(the~~recent ~~“Company”)~~fiscal ~~agreed~~years toand through the ~~terms~~date of athis ~~settlement~~Current ~~agreement~~Report ~~for~~on ~~the~~Form ~~patent~~8-K ~~infringement~~(i) ~~claims~~there ~~asserted~~were no disagreements with Frazier & ~~against~~Deeter ~~Intel~~on ~~Corporation~~any inmatter ~~Health~~of ~~Discovery~~accounting ~~Corporation~~principles v.or ~~Intel~~practices, ~~Corporation~~financial statement disclosure, ~~Case~~or ~~Nos.~~auditing ~~6:20-cv-00666-ADA~~scope ~~(W.D.~~or ~~Tex.)~~procedure, ~~6:20-cv-00356-ADA~~which, if ~~(W.D.~~not ~~Tex.).~~resolved ~~The~~to ~~agreement~~Frazier ~~provides~~& ~~for~~Deeter’s ~~the~~satisfaction, ~~payment~~would ofhave ~~$2,250,000~~caused byFrazier ~~Intel~~& ~~Corporation~~Deeter to ~~the~~make ~~Company~~reference ~~and~~to ~~release~~the ~~and~~subject ~~dismissal~~matter in ofconnection ~~all claims~~with ~~against~~their ~~Intel~~reports ~~Corporation~~on ~~with~~the ~~prejudice.~~Company’s Afinancial ~~stipulation~~statements offor ~~dismissal~~such ~~was~~years; ~~filed~~and on(ii) ~~September~~there ~~15,~~were ~~2023,~~no ~~and~~reportable ~~all~~events, within ~~asserted~~the ~~claims~~meaning ~~were dismissed~~set ~~with~~forth ~~prejudice~~in onItem ~~September~~304(a)(1)(v) ~~18,~~of ~~2023~~Regulation S-K.

The Company provided a copy of the foregoing disclosures to Frazier & Deeter prior to the date of the filing of this Current Report on Form 8-K (this “Report”) and requested that Frazier & Deeter furnish it with a letter addressed to the U.S. Securities and Exchange Commission stating whether it agrees with the above statements and, if it does not agree, the respects in which it does not agree.

The full board of directors acts as an audit committee and will be provided a copy of the 8k filing.

Item 9.01

Financial Statements and Exhibits

(d)

Exhibits

Exhibit No.	Description
16.1	Letter of Frazier & Deeter, LLC dated June 6, 2024
104	Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	HEALTH DISCOVERY CORPORATION
	Registrant
Dated: October 17, 2023	By:	/s/ Colleen Hutchinson
Dated: June 6, 2024	By:	/s/ Colleen Hutchinson
		Colleen Hutchinson Board Member

Filing Compare · HEALTH DISCOVERY CORP